Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acorda Therapeutics, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Acorda Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Acorda Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Acorda Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Acorda Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Acorda Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Acorda Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Acorda Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Acorda Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Acorda Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Acorda Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acorda Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Acorda Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Acorda Therapeutics, Inc. Snapshot 5 Acorda Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Acorda Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Acorda Therapeutics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Acorda Therapeutics, Inc. - Pipeline Products Glance 10 Acorda Therapeutics, Inc. - Late Stage Pipeline Products 10 Pre-Registration Products/Combination Treatment Modalities 10 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 Acorda Therapeutics, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Acorda Therapeutics, Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Acorda Therapeutics, Inc. - Drug Profiles 16 capsaicin 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 diazepam 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 dalfampridine ER 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 levodopa 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 cimaglermin alfa 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 rHIgM-22 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CVT-427 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Tenascin-C Fragments for Spinal Cord Injury 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Acorda Therapeutics, Inc. - Pipeline Analysis 31 Acorda Therapeutics, Inc. - Pipeline Products by Target 31 Acorda Therapeutics, Inc. - Pipeline Products by Route of Administration 32 Acorda Therapeutics, Inc. - Pipeline Products by Molecule Type 33 Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action 34 Acorda Therapeutics, Inc. - Recent Pipeline Updates 35 Acorda Therapeutics, Inc. - Dormant Projects 43 Acorda Therapeutics, Inc. - Discontinued Pipeline Products 44 Discontinued Pipeline Product Profiles 44 AC-105 44 Acorda Therapeutics, Inc. - Company Statement 45 Acorda Therapeutics, Inc. - Locations And Subsidiaries 46 Head Office 46 Other Locations & Subsidiaries 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Acorda Therapeutics, Inc., Key Information 5 Acorda Therapeutics, Inc., Key Facts 5 Acorda Therapeutics, Inc. - Pipeline by Indication, 2015 7 Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8 Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9 Acorda Therapeutics, Inc. - Pre-Registration, 2015 10 Acorda Therapeutics, Inc. - Filing rejected/Withdrawn, 2015 11 Acorda Therapeutics, Inc. - Phase III, 2015 12 Acorda Therapeutics, Inc. - Phase II, 2015 13 Acorda Therapeutics, Inc. - Phase I, 2015 14 Acorda Therapeutics, Inc. - Preclinical, 2015 15 Acorda Therapeutics, Inc. - Pipeline by Target, 2015 31 Acorda Therapeutics, Inc. - Pipeline by Route of Administration, 2015 32 Acorda Therapeutics, Inc. - Pipeline by Molecule Type, 2015 33 Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 34 Acorda Therapeutics, Inc. - Recent Pipeline Updates, 2015 35 Acorda Therapeutics, Inc. - Dormant Developmental Projects,2015 43 Acorda Therapeutics, Inc. - Discontinued Pipeline Products, 2015 44 Acorda Therapeutics, Inc., Subsidiaries 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.